Lung cancer is the leading cause of cancer-related fatalities worldwide, impacting both men and women. A major challenge is its frequent diagnosis at advanced stages, which limits treatment options. While genomic and transcriptomic analyses have traditionally been used to identify potential drug targets, there remains an unexplored potential in targeting protein-level anomalies. This study systematically investigates the proteomic landscape of 109 primary lung adenocarcinoma (LUAD) tumors using comprehensive mass-spectrometry (MS) proteomics data. By focusing on kinases, the key actors in oncogenic signaling pathways, we aim to find new therapeutic targets for LUAD. Through intricate analyses encompassing tumor-normal differentials and inter-tumor variations, our study identifies notable overexpressed targets, including PLAU, MET, ERBB2, EGFR, PDK1 kinases, and THBS2, CRABP2, INPP4B proteins, many of which present no evidence of transcriptomic alteration. Several targets we identified through proposed approaches have corresponding inhibitor drugs, including ERBB2 kinase (Afatinib) and VEGF-A protein (Bevacizumab). Our findings validate known therapeutic markers in lung cancer and reveal candidate protein targets specific to LUAD, underscoring the efficacy of proteomic methodologies in advancing precision medicine for cancer.